Stockscreener 앱 받기
10.13
7.34%
0.66
Upstream Bio Inc 주식(UPB)의 최신 뉴스
UPB: Verekitug demonstrated strong efficacy and safety in Phase 2, with Phase 3 trials set for 2027 - TradingView
Upstream Bio plans Phase 3 trials for asthma drug in Q1 2027 - Investing.com
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Upstream Bio, Inc. unveils financial results and sets Phase 3 path for verekitug - Traders Union
Upstream Bio (NASDAQ: UPB) deepens 2025 loss while推进 Phase 3 verekitug strategy - Stock Titan
Upstream Bio plans two late-stage trials for asthma, nasal polyps in 2027 - Stock Titan
Upstream Bio (NASDAQ:UPB) Trading Up 11.2%What's Next? - MarketBeat
Gainers Report: Is Upstream Bio Inc still a buy after recent gains2026 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Upstream Bio, Inc.(NasdaqGS: UPB) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Aug EndMonth: What is the next catalyst for Upstream Bio IncMarket Trend Report & Stock Timing and Entry Methods - baoquankhu1.vn
Upstream Bio Inc expected to post a loss of 70 cents a shareEarnings Preview - TradingView
UPB Stock Price, Quote & Chart | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
UPB | Upstream Bio, Inc. Common Insider Trading - Quiver Quantitative
Upstream Bio CFO Gray sells $7915 in shares - Investing.com
Upstream Bio CFO Gray sells $7915 in shares By Investing.com - Investing.com South Africa
Upstream Bio CEO Makes Notable Move With Fresh Stock Sale - TipRanks
Upstream Bio (UPB) CFO executes automatic share sale to cover RSU taxes - Stock Titan
Upstream Bio (UPB) CMO auto-sells 894 shares to cover RSU taxes - Stock Titan
Tax-related sale: Upstream Bio (UPB) CEO automatically sells 2,093 shares - Stock Titan
Tax-withholding share sale by Upstream Bio (UPB) General Counsel disclosed - Stock Titan
Tax-related stock sale by Upstream Bio (UPB) chief business officer - Stock Titan
Risk Recap: Whats next for Upstream Bio Inc stockM&A Rumor & Short-Term Swing Trade Alerts - baoquankhu1.vn
Integral Health Asset Management LLC Acquires New Stake in Upstream Bio, Inc. $UPB - MarketBeat
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB), TScan Therapeutics (TCRX) and Teladoc (TDOC) - The Globe and Mail
Upstream Bio (NASDAQ:UPB) Trading 14.4% HigherShould You Buy? - MarketBeat
UPB: Phase II data support quarterly dosing for verekitug, with phase III and COPD programs advancing - TradingView
UPB: Verekitug's quarterly dosing shows robust efficacy, with phase 3 and COPD programs advancing - TradingView
Upstream Bio, Inc. CEO joins Leerink Partners fireside chat at global healthcare conference - Traders Union
Dip Buying: Is Upstream Bio Inc forming a breakout pattern2025 Stock Rankings & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Upstream Bio's selloff may be 'overdone,' but analyst highlights asthma drug's competitive edge concerns - MSN
Aug Sectors: Can Upstream Bio Inc deliver consistent dividendsJuly 2025 Outlook & Community Verified Watchlist Alerts - baoquankhu1.vn
Lifesci Capital Forecasts Upstream Bio Q2 Earnings - MarketBeat
Brokerages Set Upstream Bio, Inc. (NASDAQ:UPB) Price Target at $45.25 - Defense World
Why Did UPB Stock Plunge 40% Today? - Stocktwits
RSI Check: Can Upstream Bio Inc outperform in the next rallyWeekly Trade Summary & Weekly Chart Analysis and Guides - baoquankhu1.vn
UPB: Verekitug shows best-in-class efficacy and safety, advancing to phase 3 with quarterly dosing - TradingView
CEO Rand Sutherland hosts live conference fireside chat, Upstream Bio, Inc. asserts - Traders Union
Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Upstream Bio presents additional Phase 2 data for verekitug - Investing.com South Africa
Upstream Bio presents additional Phase 2 data for verekitug By Investing.com - Investing.com Canada
Upstream Bio, Inc. unveils new analyses from VIBRANT Phase 2 trial at AAAAI2026 - Traders Union
Upstream Bio says primary endpoint showed reduction of -1.95 in nasal polyp score - marketscreener.com
Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score - TradingView
Upstream Bio Presents Additional Analyses from the Phase 2 - GlobeNewswire
UPB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Upstream Bio, Inc. (UPB) Stock Analysis: Exploring a 505% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Upstream Bio to present verekitug CRSwNP trial data at AAAAI By Investing.com - Investing.com Australia
Upstream Bio to present verekitug CRSwNP trial data at AAAAI - Investing.com
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 - Bitget
UPB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Latest UPB NewsUpstream Bio Reports Fourth Quarter and Full... - Stock Titan
Upstream Bio to Participate in Investor Conferences in March 2026 - geneonline.com
Peering Into Upstream Bio Inc's Recent Short Interest - Benzinga
Upstream Bio announces participation in major healthcare conferences - Traders Union
Upstream Bio to Participate in Upcoming March Investor Conferences - GlobeNewswire
0.99%
3.03%
자본화:
|
볼륨(24시간):